Overall 11.3% and 17.0% EGFR‐mutant patients with advanced‐stage NSCLC in the CTONG0901 and GLCI cohorts had BIM deletion polymorphism, respectively, which had no relationship with any clinical or pathological factors. Here, EGFR is linked to non-small cell lung carcinoma.